Trials / Completed
CompletedNCT00482079
A Study of MK0431 in Patients With Type 2 Diabetes (0431-010)
A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled Dose-Range Finding Study of MK0431 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 743 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 21 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
A dose-ranging study of MK0431 in patients with type 2 diabetes who have inadequate control of their blood sugar.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks | |
| DRUG | Comparator: placebo (unspecified) / Duration of Treatment: 21 Weeks |
Timeline
- Start date
- 2003-05-13
- Primary completion
- 2004-08-25
- Completion
- 2006-06-15
- First posted
- 2007-06-04
- Last updated
- 2017-03-28
Source: ClinicalTrials.gov record NCT00482079. Inclusion in this directory is not an endorsement.